Literature DB >> 20473069

Twenty percent of a representative sample of patients taking bupropion have abnormal, asymptomatic electroencephalographic findings.

Matthew Macaluso1, Rosey Zackula, Inna D'Empaire, Bryan Baker, Kore Liow, Sheldon H Preskorn.   

Abstract

The risk of dose-dependent seizures is a safety issue with bupropion hydrochloride. To evaluate the presence of specific electroencephalographic (EEG) waveforms, 210 adult subjects taking stable doses of bupropion hydrochloride were recruited to undergo 2 EEGs in a prospective, single-center cohort study. The occurrence of spike waves, sharp waves, and focal slowing was recorded and assessed with a continuation ratio logit model for polytomous responses. This model showed that there was a relationship between sex and the incidence of these waveforms, such that the odds of female subjects having sharp waves was increased by a factor of 2.53 (P = 0.05) when compared with male subjects and controlled for both age and dose. Similarly, female subjects were 2.45 (P = 0.09) times more likely than males to have focal slowing on EEG. Overall, 19.8% (39/197) of this representative population was found to have abnormal, asymptomatic EEG findings. The presence of these waveforms in individuals taking a medication known to lower the seizure threshold may be a risk factor for developing seizures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473069     DOI: 10.1097/JCP.0b013e3181dbe1b4

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  3 in total

1.  [Intravenous abuse of bupropione].

Authors:  N Behler; A Lehmann; B Malchow; U Palm
Journal:  Nervenarzt       Date:  2017-11       Impact factor: 1.214

Review 2.  Evaluating the evidence for sex differences: a scoping review of human neuroimaging in psychopharmacology research.

Authors:  Korrina A Duffy; C Neill Epperson
Journal:  Neuropsychopharmacology       Date:  2021-11-03       Impact factor: 7.853

Review 3.  A Framework Proposal to Follow-Up on Preclinical Convulsive Signals of a New Molecular Entity in First-in-Human Studies Using Electroencephalographic Monitoring.

Authors:  Markus Abt; Theo Dinklo; Andreas Rothfuss; Elisabeth Husar; Robert Dannecker; Katja Kallivroussis; Richard Peck; Lucette Doessegger; Christoph Wandel
Journal:  Clin Pharmacol Ther       Date:  2019-05-31       Impact factor: 6.875

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.